Virtual screening of FDA-approved drugs targeting insulin receptor (IR), integrin β1 (ITGB1), and a cluster of differentiation 36 (CD36) molecules involved both in metabolism and EMT, that would be promising in breast cancer therapy, pointed out few substances, with the opioid naldemedine among them [65]. This evidence concerns the gene INSR and breast carcinoma.